Neuroprotective effects of levetiracetam targetxCTin astrocytes in parkinsonian mice
- 10 November 2015
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 136 (1) , 194-204
Abstract
Astrocytes but not neurons express cystine/glutamate exchange transporter (xCT), which takes up cystine, and consequently supplies the substrate forGSHsynthesis in neurons. It is recognized thatGSHsynthesis in neurons is dependent on the expression ofxCTin astrocytes. Previous studies reported that levetiracetam (LEV), an anti‐epileptic drug, increasedxCTexpressionin vivo. The purpose of this study was to examine neuroprotective effects ofLEVin parkinsonian models and demonstratexCTin astrocytes as a target of neuroprotection against dopaminergic neurodegeneration. We identified striatal astrocytes cultured withLEVshowed significant increase inxCTexpression andGSHlevels. Preincubation of primary cultured mesencephalic dopamine neurons with conditioned media fromLEV‐treated astrocytes protected against 6‐hydroxydopamine (6‐OHDA)‐induced neurotoxicity. These protective effects were canceled byxCTinhibitor. Furthermore, reduction of nigrostriatal dopaminergic neurons in 6‐OHDA‐lesioned parkinsonian mice was significantly abrogated by repeated injections ofLEV. Treatment withLEVsignificantly increased the expression ofxCTin striatal astrocytes in the hemi‐parkinsonian mice. In conclusion,LEVexerts neuroprotective effects against neurodegeneration via up‐regulation ofxCTandGSHin astrocytes. Thus,xCTin astrocytes could be a potential target in novel neuroprotective approaches to prevent degeneration of dopaminergic neurons. image Glutathione (GSH) is the most potent intrinsic antioxidant. Since extracellular cysteine is readily oxidized to form cystine, cystine transport mechanisms are essential to provide cells with cysteine. Cystine uptake is mediated by cystine/glutamate exchange transporter (xCT), expressed primarily on astrocytes, but not on neurons. Astrocytes take up cystine via xCT and reduce it to cysteine to supply cysteine, the substrate for GSH synthesis in neurons. This study demonstrated that levetiracetam (LEV), an anti‐epileptic drug, increased GSH in/from astrocytes via xCT up‐regulation. GSH derived from astrocytes protects dopamine neurons against neurotoxicity induced by dopaminergic neurotoxin 6‐hydroxydopamine (6‐OHDA). Thus, xCT in astrocytes could be a potential target in novel neuroprotective approaches to prevent degeneration of dopaminergic neurons.Keywords
Funding Information
- Japan Society for the Promotion of Science (18700364, 21591082, 22590934, 25461279)
- Otsuka Pharmaceutical
This publication has 43 references indexed in Scilit:
- Remodeling of glial coverage of glutamatergic synapses in the rat nucleus tractus solitarii after ozone inhalationJournal of Neurochemistry, 2015
- Decline in arylsulfatase B and Increase in chondroitin 4‐sulfotransferase combine to increase chondroitin 4‐sulfate in traumatic brain injuryJournal of Neurochemistry, 2015
- Reactive Astrocytes As Therapeutic Targets for CNS DisordersNeurotherapeutics, 2010
- Neuroglia in neurodegenerationBrain Research Reviews, 2010
- Neuroprotective effects of zonisamide target astrocyteAnnals of Neurology, 2009
- Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's diseaseMovement Disorders, 2009
- Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s DiseaseThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmosetMovement Disorders, 2003
- Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsyEpilepsy Research, 1995
- A mechanism for glutamate toxicity in the C6 glioma cells involving inhibition of cystine uptake leading to glutathione depletionNeuroscience, 1992